This effort successfully identified an FLT3 inhibitor, AC220, that effectively synergizes with an OXPHOS inhibitor, IACS-010759, to deplete AML cells, and importantly this phenomenon was not limited to FLT3 mutant types. This evidence concerns the gene FLT3 and acute myeloid leukemia.